Skip to main content
. 1999 Sep 6;146(5):1161–1172. doi: 10.1083/jcb.146.5.1161

Figure 9.

Figure 9

Effect of the agonist anti-CD38 antibody (A10, 1:5,000 or 1:500) in the presence of substrate (1 mM NAD+) on bone resorption (a, pits per slice) and osteoclast number (b, osteoclasts per slice) as assessed in the pit assay, as well as on supernatant interleukin-6 (IL-6, ng/liter) levels (c) measured by ELISA. P values as indicated (n = 10 slices per group).